Public trust in COVID-19 vaccine science influences vaccine uptake in the US

Researchers investigate how public trust in the science of COVID-19 vaccines has changed in the United States.

Exclusive: ‘ChatGPT for DNA’: Relation nabs $35M, with Nvidia backing, for osteoporosis work

The venture arm of Nvidia, the supercomputing giant rising up the world’s most valuable companies chart, is backing a computational drug discovery startup that’s headed

March 14, 2024

AI transforms colonoscopy: Boosting detection rates, slashing miss rates in cancer screening

Researchers in China have demonstrated through a systematic review and meta-analysis that AI-based methods significantly enhance adenoma detection rates and reduce miss rates during colonoscopies,

December 4, 2023

Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn

Share this article The merger positioned Gilead to integrate CymaBay’s investigational lead product candidate, seladelpar, into its portfolio. Credit: Sundry Photography / Shutterstock.com. Gilead Sciences

March 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.